Acute Myeloid Leukemia Myelodysplastic Syndromes
Conditions
Brief summary
A single center, prospective, one arm clinical study to assess the tolerance and effectiveness of total body irradiation and cladribine in adult patients diagnosed with AML( acute myeloid leukemia) and myelodysplastic syndromes.
Interventions
DRUGCladribine
The conditioning regimen used will be cladribine-based at a dose of 5 mg / m2 for 5 days (iv.) and total body irradiation at a total dose of 12 Gy in three fractions.
Sponsors
KCRI
Maria Sklodowska-Curie National Research Institute of Oncology
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Age between 18 and 60 years. 2. Patient is a candidate for allogeneic hematopoietic cell transplantation due to acute myeloid leukemia(intermediate or high risk acute myeloid leukemia in complete remission, low risk with positive Minimal residual disease) or high risk myelodysplastic syndrome. 3. Demonstration of chemosensitivity in the case of treatment regimens with cladribine in induction therapy. 4. Patient signed informed consent form prior to any study related screening procedures are performed. 5. Patient has Eastern Cooperative Oncology Group performance status score of 0 or 1. 6. Patient is a candidate for allogeneic hematopoietic cell transplantation from sibling or unrelated donor (full matched or 9/10 mismatched) or from haploidentical donor.
Exclusion criteria
1. Has received more than 1 allogeneic hematopoietic cell transplantation. 2. Presence of active uncontrolled infection (i.e. sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection). 3. Known active human immunodeficiency virus, hepatitis B virus or hepatitis C virus infection (positive polymerase chain reaction test) or risk of hepatitis B virus reactivation (Hepatitis B surface antigen positive). 4. Presence of active disease in acute myeloid leukemia patients. 5. History or current diagnosis for uncontrolled or significant cardiac or pulmonary disease. 6. Presence of severe renal or liver dysfunction (creatinine, alanine aminotransferase,aspartate aminotransferase or bilirubin concentration \> 3.0 upper limit of normal 7. Currently pregnancy or breast feeding. 8. Treatment of any other investigational agent in the same time as this study. 9. Known allergies, hypersensitivity, or intolerance to cladribine or similar compounds. 10. Women of childbearing potential who do not agree to use two effective methods of contraception.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The probability of progression-free survival in 24 month follow up | 24 month follow up |
Secondary
| Measure | Time frame |
|---|---|
| 24-month overall survival probability | 24 month follow up |
| Disease recurrence probability. | 24 month follow up |
| Frequency of adverse events | 24 month follow up |
| Likelihood of acute and chronic graft-versus-host disease | 24 month follow up |
| Time of neutrophil and platelet implantation | 24 month follow up |
| Mortality unrelated with disease recurrence | 24 month follow up |
Countries
Poland
Outcome results
None listed